World Aids Day Campaign to Shine a Light of Hope on the HIV/AIDS Epidemic in the United States

Bristol-Myers Squibb Company (NYSE: BMY)Bristol-Myers Squibb Company (NYSE: BMY) in collaboration with the National AIDS Fund (NAF) launched the fourth annual "Light to Unite" campaign in support of World AIDS Day. Light to Unite shines a light on the ongoing HIV/AIDS epidemic in the U.S. and encourages individuals to get involved in the struggle against the disease through the sharing of knowledge and experiences, and through donations that benefit grassroots HIV/AIDS organizations throughout the country.

The Catawba Care Coalition, a community-based HIV testing and counseling center in rural South Carolina, is one of the many HIV/AIDS organizations throughout the U.S. that is able to help individuals in need, in part because of donations from last year's Light to Unite campaign.

"Nearly one in four people with HIV in the U.S. do not know they have it," said Anita Case, executive director of Catawba Care Coalition. "Because of Light to Unite, we've been able to significantly increase our outreach to get people tested and counseled, link them to care if infected, and when they're negative, teach them prevention techniques to make sure they stay negative."

"While progress has been made with new treatments and prevention strategies, we still see 40,000 new HIV infections diagnosed every year in the United States. That is 40,000 too many!" said Kandy Ferree, president and CEO, the National AIDS Fund. "Increasingly, those being impacted by HIV/AIDS live in rural areas, far from information and treatment centers, or live in poverty, unable to access information. We have to go to them. Collaborations, like ours with Bristol-Myers Squibb, can help to change the course of this disease in the United States."

In the United States:

  • An estimated one million people are living with HIV/AIDS.
  • One in four new HIV/AIDS infections is in women.
  • African Americans account for 49 percent of all new HIV/AIDS cases despite representing only about 13 percent of the total population.
  • Every 15 minutes one American becomes infected with HIV.
  • The rate of new HIV/AIDS infections has not declined in over 15 years.
  • The South represents a little more than one third of the population, yet now accounts for nearly half of the estimated number of new AIDS cases.

"Through Light to Unite, Bristol-Myers Squibb is encouraging everyone to help us shine a light on the ongoing HIV/AIDS epidemic in the United States and make a difference in the lives of people with this disease," said Anthony Hooper, president, U.S. Pharmaceuticals, Bristol-Myers Squibb Company. "Our collaboration with the National AIDS Fund helps ensure that the communities hardest hit by the HIV/AIDS epidemic receive critical patient services and support."

The focal point of the Light to Unite campaign is the Web site, http://www.lighttounite.org, where each individual who participates in the campaign can "shine a light" by lighting a virtual candle while learning new facts about HIV/AIDS, sharing stories of personal impact, and giving directly to the National AIDS Fund.

To commemorate this year's World AIDS Day and Light to Unite, Bristol- Myers Squibb is making a $250,000 contribution to the National AIDS Fund, which will be distributed through grants to help organizations provide important services to HIV/AIDS patients, such as treatment, care and prevention programs. One hundred percent of the contribution will be distributed to grant recipients.

The National AIDS Fund provides grants through a network of more than 400 grassroots HIV/AIDS organizations around the country. This approach gives grassroots HIV/AIDS organizations access to needed funding, to offer support services that best meet the needs of their local communities.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Visit Bristol-Myers Squibb at http://www.bms.com.

About the National AIDS Fund
The National AIDS Fund's mission is to reduce the incidence and impact of HIV/AIDS by promoting leadership and generating resources for effective community responses to the epidemic. Through an expanding network of Community Partnerships, the National AIDS Fund promotes collaborative local planning and provides strategic grants and technical support to nearly 400 direct service organizations annually. Since 1988, together with its Community Partnerships, the National AIDS Fund has invested over $142 million to combat the AIDS epidemic in the United States. For more information about the National AIDS Fund, please visit http://www.aidsfund.org.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

In mice, stem cells seem to work in fighting obesi…

Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for ...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Research shows how a moderate dose of alcohol prot…

For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A stu...

'Kiss of death' cancer

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negativ...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...